Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Biochimica et Biophysica Acta

• Publication date

  2010-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bbadis.2010.05.003PMID 20471476
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease.

  2010cited by this paper
• Fabry disease.

  2009cited by this paper
• New equations to estimate GFR in children with CKD.

  2009cited by this paper
• [Fabry disease].

  2009cited by this paper
• Enzyme activity for determination of presence of Fabry disease in women results in 40% false-negative results.

  2008cited by this paper
• Elevated globotriaosylsphingosine is a hallmark of Fabry disease

  2008cited by this paper
• HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma.

  2007cited by this paper
• Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life

  2007cited by this paper
• Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease

  2007cited by this paper
• Vascular effects of sphingolipids

  2007cited by this paper
• The Dutch Fabry cohort: Diversity of clinical manifestations and Gb3 levels

  2007cited by this paper
• Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg

  2007cited by this paper
• The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature.

  2006influential reference
• Increased carotid intima–media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease

  2006cited by this paper
• Manifestations of Fabry disease in placental tissue

  2006cited by this paper
• Structural and functional changes in peripheral vasculature of Fabry patients

  2006cited by this paper
• Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate

  2006cited by this paper
• Is globotriaosylceramide a useful biomarker in Fabry disease?

  2005cited by this paper
• Monitoring enzyme replacement therapy in Fabry disease—Role of urine globotriaosylceramide

  2005cited by this paper
• Natural history of Fabry disease in females in the Fabry Outcome Survey

  2005cited by this paper
• The Relationship of Vascular Glycolipid Storage to Clinical Manifestations of Fabry Disease: A Cross-Sectional Study of a Large Cohort of Clinically Affected Heterozygous Women

  2005cited by this paper
• The Mainz Severity Score Index: a new instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapy

  2004cited by this paper
• Recombinant Enzyme Therapy for Fabry Disease: Absence of Editing of Human α-Galactosidase A mRNA

  2003cited by this paper
• UvA-DARE ( Digital Academic Repository ) Recombinant enzyme therapy for Fabry disease : absence of editing of human alpha-galactosidase A mRNA

  2002cited by this paper
• Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients

  2002cited by this paper
• Arterial remodelling in Fabry disease

  2002cited by this paper
• Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

  2001cited by this paper
• The Metabolic and Molecular Bases of Inherited Disease

  2001cited by this paper
• Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

  2001cited by this paper
• Anderson–Fabry disease: Clinical manifestations of disease in female heterozygotes

  2001cited by this paper
• Natural history of Fabry disease in affected males and obligate carrier females

  2001cited by this paper
• Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry's disease

  2001cited by this paper
• Cerebrovascular complications of Fabry's disease

  1996cited by this paper
• An atypical variant of Fabry's disease in men with left ventricular hypertrophy.

  1995cited by this paper
• An atypical variant of Fabry's disease with manifestations confined to the myocardium.

  1991cited by this paper
• Stratifying the patient at risk from coronary disease: new insights from the Framingham Heart Study.

  1990cited by this paper
• Demonstration of Fabry's disease deposits in placenta.

  1990cited by this paper
• [Alpha-galactosidase A deficiency--Fabry's disease].

  1988cited by this paper
• Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study.

  1987cited by this paper
• Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.

  1967cited by this paper
• FABRY'S DISEASE: CLASSIFICATION AS A SPHINGOLIPIDOSIS AND PARTIAL CHARACTERIZATION OF A NOVEL GLYCOLIPID.

  1963cited by this paper

• Coexistence of Alport Syndrome and Fabry Disease in a Female with R112H Variant: Early Progression of Fabry Nephropathy

  2025influential citation
• Prevalence and Clinical Correlates of Cerebrovascular Alterations in Fabry Disease: A Cross-Sectional Study

  2025cites this paper
• Czech nationwide screening for Fabry disease in patients on maintenance dialysis: a call for evaluation of population-enriched GLA gene variants of uncertain significance

  2025cites this paper
• Cardiac Magnetic Resonance Guidance for the Pathogenetic Definition of Cardiomyopathies

  2025cites this paper
• Association of the rs823144 variant of the RAB29 gene with the activity of lysosomal hydrolases in blood cells and risk of Parkinson’s disease

  2025cites this paper
• Unexpected Hypotension in a Female Patient with Fabry Disease: Switching from Agalsidase α to β after Long-term ERT

  2025cites this paper
• Fabry disease in Argentina: clinical, biochemical and molecular correlation in all reported GLA variants.

  2025cites this paper
• Fabry Disease Nephropathy: Compendium of “in vitro” and “in vivo” Renal Effects of Globotriaosylsphingosine

  2025cites this paper
• Real-world clinical outcomes in adult patients with Fabry disease: A 20-year retrospective observational cohort study from a single centre

  2025cites this paper
• The use and performance of lyso-Gb3 for the diagnosis and monitoring of Fabry disease: A systematic literature review.

  2025cites this paper
• Long-term safety of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: post-marketing extension surveillance in Japan

  2024cites this paper
• Phenotypic Evolution in Fabry Disease: Our Experience in Indian Cohort

  2024cites this paper
• Late-onset renal variant Fabry disease with R112H mutation and mild increase in plasma globotriaosylsphingosine: a case report

  2024cites this paper
• Diagnosis of Fabry Disease Using Alpha-Galactosidase A Activity or LysoGb3 in Blood Fails to Identify Up to Two Thirds of Female Patients

  2024cites this paper
• c.640-814 T > C mutation in deep intronic region of alpha-galactosidase A gene is associated with Fabry disease via dominant-negative effect.

  2024cites this paper
• Infrared spectroscopy as a new approach for early fabry disease screening: a pilot study

  2024cites this paper
• Glycosphingolipids and their impact on platelet activity in a murine model of fabry disease

  2024cites this paper
• Biomarkers in anderson-Fabry disease: what should we use in the clinical practice?

  2024cites this paper
• Potential Usefulness of Lifetime Globotriaosylsphingosine Exposure at Diagnosis and Baseline Modified Disease Severity Score in Early-Diagnosed Patients With Fabry Disease

  2024influential citation
• Fabry disease phenotyping in women from the complete Romanian cohort – time for early diagnostic awareness

  2024cites this paper
• Rapidly progressive cognitive impairment resulting in heavy psychosocial burden in a patient with Fabry disease undergoing hemodialysis: a case report

  2024cites this paper
• A phase III, open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies

  2024influential citation
• Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis

  2024cites this paper
• Fabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations

  2023cites this paper
• Biochemical Mechanisms beyond Glycosphingolipid Accumulation in Fabry Disease: Might They Provide Additional Therapeutic Treatments?

  2023cites this paper
• Sex Differences in Anderson–Fabry Cardiomyopathy: Clinical, Genetic, and Imaging Analysis in Women

  2023cites this paper
• An expert consensus on the recommendations for the use of biomarkers in Fabry disease.

  2023cites this paper
• Anderson-Fabry disease cardiomyopathy: an update on epidemiology, diagnostic approach, management and monitoring strategies

  2023cites this paper
• Profiles of Globotriaosylsphingosine Analogs and Globotriaosylceramide Isoforms Accumulated in Body Fluids from Various Phenotypic Fabry Patients

  2023cites this paper
• Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease.

  2023cites this paper
• Early Risk Stratification for Natural Disease Course in Fabry Patients Using Plasma Globotriaosylsphingosine Levels

  2023cites this paper
• Could immune cells be associated with nephropathy in Fabry disease patients?

  2023cites this paper
• Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: a multidisciplinary Turkey perspective

  2022cites this paper
• A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease

  2022cites this paper
• Development of Lanzyme as the Potential Enzyme Replacement Therapy Drug for Fabry Disease

  2022cites this paper
• Recurrent Cerebrovascular Complications under Enzyme Replacement Therapy in a Patient with Fabry Disease on Peritoneal Dialysis

  2022cites this paper
• The Heart in Fabry Disease: Mechanisms Beyond Storage and Forthcoming Therapies

  2022cites this paper
• Fabry Disease Cardiomyopathy: A Review of the Role of Cardiac Imaging from Diagnosis to Treatment

  2022cites this paper
• Growth Differentiation Factor-15 and Syndecan-1 Are Potential Biomarkers of Cardiac and Renal Involvement in Classical Fabry Disease under Enzyme Replacement Therapy

  2022cites this paper
• Influence of initial clinical suspicion on the diagnostic yield of laboratory enzymatic testing in lysosomal storage disorders. Experience from a multispecialty hospital.

  2022cites this paper
• Identification of dual active sites in Caenorhabditis elegans GANA-1 protein: an ortholog of the human α-GAL a and α-NAGA enzymes

  2022cites this paper
• Fabry disease in the practice of a neurologist

  2022cites this paper
• X Chromosome Inactivation in Carriers of Fabry Disease: Review and Meta-Analysis

  2021cites this paper
• Comparative urinary globotriaosylceramide analysis by thin-layer chromatography-immunostaining and liquid chromatography-tandem mass spectrometry in patients with Fabry disease

  2021cites this paper
• Biomarkers in Fabry Disease. Implications for Clinical Diagnosis and Follow-up

  2021cites this paper
• Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease

  2021cites this paper
• Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions

  2021cites this paper
• Circulating miR-184 is a potential predictive biomarker of cardiac damage in Anderson–Fabry disease

  2021cites this paper
• Challenging the traditional approach for interpreting genetic variants: Lessons from Fabry disease

  2021cites this paper
• Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression.

  2021cites this paper
• Newborn Screening for Fabry Disease in Northeastern Italy: Results of Five Years of Experience

  2021cites this paper
• Developments in the treatment of Fabry disease

  2020cites this paper
• Development of Strategies to Decrease False Positive Results in Newborn Screening

  2020cites this paper
• Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis

  2020cites this paper
• Fabry disease pain: patient and preclinical parallels

  2020influential citation
• Screening for Fabry Disease in Young Strokes in the Australian Stroke Clinical Registry (AuSCR)

  2020cites this paper
• Maladie de Fabry : quand y penser ?

  2020cites this paper
• Biomarkers in Anderson–Fabry Disease

  2020cites this paper
• [Fabry disease: A review].

  2020cites this paper
• Fabry Disease on Peritoneal Dialysis with Cardiac Involvement

  2020cites this paper
• Biomarkers of Fabry Nephropathy: Review and Future Perspective

  2020cites this paper
• Effects of agalsidase-β administration on vascular function and blood pressure in familial Anderson–Fabry disease

  2020cites this paper
• Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy

  2020cites this paper
• Stratification of Fabry mutations in clinical practice: a closer look at α‐galactosidase A‐3D structure

  2020cites this paper
• An expert consensus document on the management of cardiovascular manifestations of Fabry disease

  2020cites this paper
• Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: Phase I and II/III clinical studies.

  2020cites this paper
• Multiplexed derivatization strategy-based dummy molecularly imprinted polymers as sorbents for magnetic dispersive solid phase extraction of globotriaosylsphingosine prior to UHPLC-MS/MS quantitation

  2020cites this paper
• Narrative review on Morbus Fabry: diagnosis and management of cardiac manifestations.

  2020cites this paper
• Laboratory Diagnosis of Lysosomal Diseases: Newborn Screening to Treatment.

  2020cites this paper
• JIMD Reports, Volume 45

  2019cites this paper
• Significant hearing loss in Fabry disease: Study of the Danish nationwide cohort prior to treatment

  2019cites this paper
• FAbry STabilization indEX (FASTEX): Clinical evaluation of disease progression in Fabry patients.

  2019cites this paper
• Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study.

  2019cites this paper
• The clinical utility of total concentration of urinary globotriaosylsphingosine plus its analogues in the diagnosis of fabry disease.

  2019cites this paper
• Translational readthrough of GLA nonsense mutations suggests dominant-negative effects exerted by the interaction of wild-type and missense variants

  2019cites this paper
• Early Biomarkers of Fabry Nephropathy: A Review of the Literature

  2019cites this paper
• Assessment of Cardiac Involvement in Fabry Disease (FD) with Native T1 Mapping

  2019cites this paper
• Usefulness of lyso-globotriaosylsphingosine in dried blood spots in the differential diagnosis between multiple sclerosis and Anderson-Fabry's disease.

  2019cites this paper
• Elevated Lyso-Gb3 Suggests the R118C GLA Mutation Is a Pathological Fabry Variant.

  2019cites this paper
• Global glycosphingolipid analysis in urine and plasma of female Fabry disease patients.

  2019cites this paper
• Dorsal root ganglia volume is increased in patients with the Fabry-related GLA variant p.D313Y

  2019cites this paper
• Sphingolipids as Biomarkers of Disease.

  2019cites this paper
• α-Galactosidase A/lysoGb3 ratio as a potential marker for Fabry disease in females.

  2019cites this paper
• Treatment in Fabry disease

  2018cites this paper
• Dissociation of globotriaosylceramide and impaired endothelial function in α-galactosidase-A deficient EA.hy926 cells.

  2018cites this paper
• Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?

  2018cites this paper
• Development and clinical consequences of white matter lesions in Fabry disease: a systematic review.

  2018cites this paper
• Treatment in Fabry disease.

  2018cites this paper
• Early markers of heart and kidney damage in Fabry disease

  2018cites this paper
• Storage diseases with hypertrophic cardiomyopathy phenotype

  2018cites this paper
• Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation

  2018cites this paper
• Contribution of tandem mass spectrometry to the diagnosis of lysosomal storage disorders

  2018cites this paper
• Investigation of correlation of urinary globotriaosylceramide (Gb3) levels with markers of renal function in patients with Fabry disease.

  2018cites this paper
• Fabry Nephropathy: An Evidence-Based Narrative Review

  2018cites this paper
• CD77 levels over enzyme replacement treatment in Fabry Disease Family (V269M)

  2018cites this paper
• Clinical significance of plasma globotriaosylsphingosine levels in Chinese patients with Fabry disease

  2018influential citation
• Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis

  2018cites this paper
• Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy

  2018cites this paper
• Screening for Fabry Disease in Japanese Patients with Young-Onset Stroke by Measuring α-Galactosidase A and Globotriaosylsphingosine.

  2018cites this paper
• Development and Analytical Characterization of Pegunigalsidase Alfa, a Chemically Cross-Linked Plant Recombinant Human α-Galactosidase-A for Treatment of Fabry Disease.

  2018cites this paper